Treace Medical Concepts, Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 6, 2024 and accepted by EDGAR at Aug 6, 2024, 16:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $44.5m | us-gaap:Revenues |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $95.6m | us-gaap:Revenues |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $8.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $18.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-04-01 to 2024-06-30 | $35.7m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-01-01 to 2024-06-30 | $76.7m | us-gaap:GrossProfit |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $5.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $10.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$21.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$40.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $1.3m | us-gaap:InterestExpense |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $2.6m | us-gaap:InterestExpense |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$21.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$39.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | −$0.34 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | −$0.64 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | −$0.34 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | −$0.64 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 62,081,494 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 61,937,140 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$21.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-01-01 to 2024-06-30 | $5.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-06-30 | $18.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $171.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $226.1m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $44.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $113.9m | us-gaap:Liabilities |
| Long-term debt | At period end2024-06-30 | $53.2m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2024-06-30 | $112.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-091787. Last ingested by Listed: Oct 29, 2026, 04:31 ET. Listed shows no prices and gives no investment advice.